undefined
undefined
Number
Title
Date
1
[Financial Economy Plus] CRISPR, Part 4: Opening Act of a ‘Licensing Boom’—ToolGen Steps Beyond a Royalty Hub to the Center of Global Collaboration
2026.03.02
2
[Financial Economy Plus] CRISPR, Part 3: Platform Advantage — “Time Is on ToolGen’s Side” as Protracted Disputes Prolong Monopoly Terms
2026.03.01
3
[Financial Economy Plus] CRISPR, Part 2: “Find Biotech’s ARM” — The Power of the ‘Standard Technology’ Dominating Gene Editing
2026.02.28
4
[Financial Economy Plus] CRISPR, Part 1: From Probability to Design as FDA Redraws the Gene‑Editing Profit Formula
2026.02.27
5
[Finance Economy Plus] “Patents are the sword; royalties are the shield” — ToolGen declares 2026 its inaugural year for monetizing gene‑editing “scissors.”
2026.02.18
6
[Press Release] ToolGen Enters 'Harvest Season' for Global IP Monetization ; Appoints Litigation & Negotiation Expert Dave Koo as CLO
2026.02.12
7
[Notice] CRISPR RNP Patent Status update(US,EU)
2026.02.04
8
[Biz watch] ToolGen Speeds Up in H1 Amid 10‑Year Patent Dispute
2026.01.27
9
[BIO Insight] ToolGen, Confident in Patent Battle Win: ‘We’ll Commercialize Gene‑Editing IP’
2026.01.25
10
[Notice] ToolGen Secures Decision to Resume CRISPR-Cas9 Interference Proceedings as Senior Party
2026.01.21
11
[Notice] Frequently Asked Questions (FAQ)
2026.01.15
12
[MoneyToday] MoneyToday Power Interview
2025.12.26
13
[Notice] CRISPR RNP Patent Status(US,EU)
2025.12.24
14
[NATV] Policy Seminar on Securing Growth Drivers for the Advanced Bio Industry
2025.11.21
15
[Notice] U.S. Patent Registration Certificate (CRISPR RNP)
2025.11.18